Abstract
A fundamental question of any program focused on the testing and timely diagnosis of a communicable disease is its effectiveness in reducing community transmission. Unfortunately, direct estimation of this effectiveness is difficult in practice, elevating the value of mathematical modeling that can predict it from first principles. Here, we introduce testing effectiveness (TE), defined as the fraction by which transmission is reduced via testing and post-diagnosis isolation at the population scale, and develop a mathematical model that estimates it from the interactions of tests, within-host pathogen dynamics, and arbitrarily complex testing behaviors. While our model generalizes across pathogens, we demonstrate its flexibility through an analysis of three respiratory pathogens, influenza A, respiratory syncytial virus (RSV), and both pre-vaccine and post-vaccine era SARS-CoV-2, quantifying TE across post-exposure, post-symptom, and routine testing scenarios. We show that TE varies considerably by strategy and pathogen, with optimal testing depending on the number of tests available and when they are used. This work quantifies tradeoffs about when and how to test, providing a flexible framework to guide the use and development of current and future diagnostic tests to control transmission of infectious diseases.
Competing Interest Statement
D.B.L. is a member of the scientific advisory board of Darwin BioSciences and discloses past consulting for Flambeau RapidX.
Funding Statement
C.E.M. was supported in part by the Interdisciplinary Quantitative Biology (IQBio) program at the University of Colorado Boulder and by the SeroNet program of the National Cancer Institute (1U01CA261277-01). D.B.L. was supported in part by an NSF Alan T. Waterman Award (SMA-2226343).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes